What is denosumab-bbdz?

Denosumab-bbdz is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor kappa-B ligand). Denosumab-bbdz has an approximate molecular weight of 147 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells. Jubbonti (denosumab-bbdz) injection is a sterile, preservative-free, clear to slightly opalescent and colorless to slightly yellowish to slightly brownish solution for subcutaneous use. Each single-dose prefilled syringe contains 1 mL solution of 60 mg denosumab-bbdz, glacial acetic acid (1.021 mg), polysorbate 20 (0.1 mg), sodium hydroxide (0.499 mg), sorbitol (47 mg), and Water for Injection (USP). Hydrochloric acid and sodium hydroxide may be added to adjust the pH to 5.2.

Can you take denosumab-bbdz with other medicines?

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run denosumab-bbdz against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

What brand names is denosumab-bbdz sold under?

We track 2 denosumab-bbdz-containing products in the U.S.: Jubbonti and Wyost. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

What forms does denosumab-bbdz come in?

Across the brands we track, denosumab-bbdz is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Is there a generic denosumab-bbdz?

We do not currently list a generic-labelled denosumab-bbdz product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.

Denosumab-Bbdz: uses, dosing, side effects & brands

Denosumab-Bbdz is a medicine sold in the U.S. under 2 brand and generic names, for postmenopausal osteoporosis and osteoporotic fractures. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.

By the pharmaranks editorial teamReviewed against the FDA (openFDA label, NDC Directory & Enforcement) sourcesHow we research

Key facts

Treats: Postmenopausal Osteoporosis and Osteoporotic Fractures
Available as: Injectable
Sold as: 2 products — Jubbonti and Wyost
Prescription?: Prescription only
Generic available?: Not in our catalog
Boxed warning: Boxed warning

How denosumab-bbdz is dosed

From the FDA label for Jubbonti (application BLA761362). Other denosumab-bbdz products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.

Pregnancy must be ruled out prior to administration of Jubbonti. ( 2.1 ) • Before initiating Jubbonti in patients with advanced chronic kidney disease, including dialysis patients, evaluate for the presence of chronic kidney disease mineral and bone disorder with intact parathyroid hormone, serum calcium, 25(OH) vitamin D, and 1,25 (OH) 2 vitamin D. ( 2.2 , 5.1 , 8.6 ) • Jubbonti should be administered by a healthcare provider. ( 2.3 ) • Administer 60 mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen. ( 2.3 ) • Instruct patients to take calcium 1000 mg daily and at least 400 IU vitamin D daily. ( 2.3 ) 2.1 Pregnancy Testing Prior to Initiation of Jubbonti Pregnancy must be ruled out prior to administration of Jubbonti. Perform pregnancy testing in all females of reproductive potential prior to administration of Jubbonti. Based on findings in animals, denosumab products can cause fetal harm when administered to pregnant women [see Use in Specific Populations ( 8.1, 8.3) ] . 2.2 Laboratory Testing in Patients with Advanced Chronic Kidney Disease Prior to Initiation of Jubbonti In patients with advanced chronic kidney disease [i.e., estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m 2 ], including dialysis-dependent patients, evaluate for the presence of chronic kidney disease mineral and bone…

Denosumab-Bbdz side effects

The following serious adverse reactions are discussed below and also elsewhere in the labeling: • Severe Hypocalcemia and Mineral Metabolism Changes [see Warnings and Precautions ( 5.1 )] • Hypersensitivity [see Warnings and Precautions ( 5.3 )] • Osteonecrosis of the Jaw [see Warnings and Precautions ( 5.4 )] • Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions ( 5.5 )] • Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation [see Warnings and Precautions ( 5.6 )] • Serious Infections [see Warnings and Precautions ( 5.7 )] • Dermatologic Adverse Reactions [see Warnings and Precautions ( 5.8 )] The most common adverse reactions reported with denosumab products in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis. The most common adverse reactions reported with denosumab products in men with osteoporosis are back pain, arthralgia, and nasopharyngitis. The most common adverse reactions reported with denosumab products in patients with glucocorticoid-induced osteoporosis are back pain, hypertension, bronchitis, and headache. The most common (per patient incidence ≥ 10%) adverse reactions reported with denosumab products in patients with bone loss receiving androgen deprivation therapy for prostate cancer or adjuvant aromatase inhibitor therapy…

Every denosumab-bbdz product we track (2)

Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.

Denosumab-Bbdz products
#	Drug	Rating	Type	Form	Generic?	Typical price
1	Jubbonti Boxed warning	64/100	Prescription	Injectable	—	—	View →
2	Wyost

Frequently asked questions

What is denosumab-bbdz?: Denosumab-bbdz is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor kappa-B ligand). Denosumab-bbdz has an approximate molecular weight of 147 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells. Jubbonti (denosumab-bbdz) injection is a sterile, preservative-free, clear to slightly opalescent and colorless to slightly yellowish to slightly brownish solution for subcutaneous use. Each single-dose prefilled syringe contains 1 mL solution of 60 mg denosumab-bbdz, glacial acetic acid (1.021 mg), polysorbate 20 (0.1 mg), sodium hydroxide (0.499 mg), sorbitol (47 mg), and Water for Injection (USP). Hydrochloric acid and sodium hydroxide may be added to adjust the pH to 5.2.
Can you take denosumab-bbdz with other medicines?: It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run denosumab-bbdz against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is denosumab-bbdz sold under?: We track 2 denosumab-bbdz-containing products in the U.S.: Jubbonti and Wyost. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does denosumab-bbdz come in?: Across the brands we track, denosumab-bbdz is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic denosumab-bbdz?: We do not currently list a generic-labelled denosumab-bbdz product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.

Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.